Biosig completes enrollment in the pure ep 2.0 clinical study

Westport, ct, april 13, 2021 (globe newswire) -- biosig technologies, inc. (nasdaq: bsgm) (“biosig” or the “company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ecg and intra-cardiac signals, today announced it completed enrollment in the pure ep 2.0 clinical trial.
BSGM Ratings Summary
BSGM Quant Ranking